303 related articles for article (PubMed ID: 9598623)
21. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
22. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
23. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population.
Mungan AG; Erol B; Akduman B; Bozdogan G; Kiran S; Yesilli C; Mungan NA
Clin Chem Lab Med; 2007; 45(7):912-6. PubMed ID: 17617037
[TBL] [Abstract][Full Text] [Related]
24. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
25. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
Dinçel C; Caşkurlu T; Taşçi AI; Cek M; Sevin G; Fazlioğlu A
Int Urol Nephrol; 1999; 31(4):497-509. PubMed ID: 10668945
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
Saika T; Tsushima T; Nasu Y; Kusaka N; Miyaji Y; Takamoto H; Takeda K; Uno S; Kumon H;
Cancer; 2002 Mar; 94(6):1685-91. PubMed ID: 11920529
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer detection in candidates for open prostatectomy.
Fowler JE; Bigler SA; Kolski JM
J Urol; 1998 Dec; 160(6 Pt 1):2107-10. PubMed ID: 9817333
[TBL] [Abstract][Full Text] [Related]
29. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
Erol B; Gulpinar MT; Bozdogan G; Ozkanli S; Onem K; Mungan G; Bektas S; Tokgoz H; Akduman B; Mungan A
Kaohsiung J Med Sci; 2014 Nov; 30(11):545-50. PubMed ID: 25458043
[TBL] [Abstract][Full Text] [Related]
30. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
31. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report.
Babaian RJ; Fritsche HA; Zhang Z; Zhang KH; Madyastha KR; Barnhill SD
Urology; 1998 Jan; 51(1):132-6. PubMed ID: 9457308
[TBL] [Abstract][Full Text] [Related]
34. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
35. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.
Sershon PD; Barry MJ; Oesterling JE
Eur Urol; 1994; 25(4):281-7. PubMed ID: 7519989
[TBL] [Abstract][Full Text] [Related]
36. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
Oesterling JE; Jacobsen SJ; Klee GG; Pettersson K; Piironen T; Abrahamsson PA; Stenman UH; Dowell B; Lövgren T; Lilja H
J Urol; 1995 Sep; 154(3):1090-5. PubMed ID: 7543605
[TBL] [Abstract][Full Text] [Related]
37. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
[TBL] [Abstract][Full Text] [Related]
38. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
39. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen adjusted for the transition zone volume versus free-to-total prostate-specific antigen ratio in predicting prostate cancer.
Moon DG; Cheon J; Kim JJ; Yoon DK; Koh SK
Int J Urol; 1999 Sep; 6(9):455-62. PubMed ID: 10510891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]